COPENHAGEN / LONDON (IT BOLTWISE) – Novo Nordisk is facing challenges in the GLP-1 market as the company had to lower its 2025 sales forecast again. Despite growth in sales of Wegovy and Ozempic, the Danish pharmaceutical giant faces intense competition and regulatory hurdles. However, the strategic partnerships and expansion into new markets could offer new growth opportunities.
Today’s daily deals at Amazon! ˗ˋˏ$ˎˊ˗
Novo Nordisk, a leading provider of diabetes and obesity medicines, has lowered its 2025 sales forecast for the third time this year. The company now expects revenue growth of 8% to 11%, a significant reduction from its original forecast of 16% to 24%. This adjustment follows disappointing results in the third quarter, where sales missed expectations.
Sales of Wegovy, a weight-loss drug, rose nearly 18% to $3.13 billion but fell short of expectations. Ozempic, another key Novo Nordisk product, posted sales of $4.73 billion, meeting forecasts. Despite these successes, the company faces intense competition, particularly from Eli Lilly, whose Zepbound and Mounjaro products posted strong growth in the third quarter.
Karsten Munk Knudsen, chief financial officer of Novo Nordisk, emphasizes that after a period of “hyper growth,” the company is now facing a slower growth rate. This is due to increasing competition and challenges in market penetration. Novo Nordisk is responding by expanding into the cash pay market and partnering with retail giants like Costco and Sam’s Club.
Another strategic step is the planned launch of an oral version of Wegovy, which could be the first oral GLP-1 drug for weight loss. Novo Nordisk is also in negotiations to acquire Metsera to further strengthen its position in the market for GLP-1 drugs. These steps could help the company consolidate its market position and explore new growth opportunities.
Order an Amazon credit card without an annual fee with a credit limit of 2,000 euros!
Bestseller No. 1 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 2 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 3 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 4 ᵃ⤻ᶻ «KI Gadgets»
Bestseller No. 5 ᵃ⤻ᶻ “KI Gadgets”
Please send any additions and information to the editorial team by email to de-info[at]it-boltwise.de. Since we cannot rule out AI hallucinations, which rarely occur with AI-generated news and content, we ask you to contact us via email and inform us in the event of false statements or misinformation. Please don’t forget to include the article headline in the email: “Novo Nordisk: Challenges and opportunities in the GLP-1 market”.